Phibro Animal Health CEO Sells Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 23 2026
0mins
Source: NASDAQ.COM
- Share Reduction Details: Jack Bendheim, CEO of Phibro Animal Health, sold 18,608 shares of common stock between May 5 and May 7, 2026, representing about 20% of his total reported ownership, indicating a gradual reduction in his stake in the company.
- Transaction Value Analysis: The sale, calculated at a weighted average purchase price of $54.61 per share according to SEC Form 4, reflects a significant transaction value, although Bendheim retains a solid ownership stake, suggesting confidence in the company's future.
- Management Transition Context: Bendheim established the sale plan in December 2025, coinciding with his announcement to step down as CEO on July 1, 2026, transitioning to Executive Chairman, which provides a reasonable context for his gradual divestment, typical for founder-era executives.
- Future Outlook and Challenges: With Daniel Bendheim taking over, investor focus will shift to sustaining the integration of Phibro's recent acquisition of Zoetis' feed additive portfolio and maintaining margin expansion, which will directly impact the company's long-term growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAHC
Wall Street analysts forecast PAHC stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 30.790
Low
45.00
Averages
47.50
High
50.00
Current: 30.790
Low
45.00
Averages
47.50
High
50.00
About PAHC
Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phibro Animal Health CEO Sells Shares Amid Transition
- Share Reduction Details: Jack Bendheim, CEO of Phibro Animal Health, indirectly sold 18,608 shares of common stock between May 5 and May 7, 2026, totaling approximately $1 million, which reduced his indirect holdings from 74,760 to 56,152 shares, indicating a potential decrease in confidence regarding the company's future.
- Trading Plan Context: This sale was executed under a Rule 10b5-1 trading plan established on December 11, 2025, reflecting Bendheim's strategic adjustment ahead of his transition from CEO to Executive Chairman, suggesting a cautious approach during the governance change.
- Ownership Analysis: Despite the sale, Bendheim retains 16,840 direct shares and 56,152 indirect shares, totaling 449,485 Class A common stock shares convertible into common stock, indicating he still maintains significant economic interest and influence within the company.
- Company Performance Overview: Phibro Animal Health reported a revenue of $1.5 billion and a net income of $95.23 million, with a dividend yield of 1.88% and a 50.21% increase in stock price over the past year, highlighting the company's strong performance and growth potential in the animal health product market.
See More
Phibro Animal Health CEO Sells Shares
- Share Reduction Details: Jack Bendheim, CEO of Phibro Animal Health, sold 18,608 shares of common stock between May 5 and May 7, 2026, representing about 20% of his total reported ownership, indicating a gradual reduction in his stake in the company.
- Transaction Value Analysis: The sale, calculated at a weighted average purchase price of $54.61 per share according to SEC Form 4, reflects a significant transaction value, although Bendheim retains a solid ownership stake, suggesting confidence in the company's future.
- Management Transition Context: Bendheim established the sale plan in December 2025, coinciding with his announcement to step down as CEO on July 1, 2026, transitioning to Executive Chairman, which provides a reasonable context for his gradual divestment, typical for founder-era executives.
- Future Outlook and Challenges: With Daniel Bendheim taking over, investor focus will shift to sustaining the integration of Phibro's recent acquisition of Zoetis' feed additive portfolio and maintaining margin expansion, which will directly impact the company's long-term growth potential.
See More
Phibro Animal Health to Attend Stifel Conference
- Conference Participation: Phibro Animal Health Corporation will participate in the Stifel Jaws & Paws Conference on May 27, 2026, where executives will present the company's strategic and financial outlook, potentially boosting investor confidence.
- Executive Lineup: CEO designate Daniel Bendheim, COO Larry Miller, and CFO Glenn David will attend, showcasing the leadership team's expertise and commitment to future growth, which may attract more investor interest.
- Live and Replay Availability: The live audio presentation will be accessible on Phibro's Investor Relations website, with an archived replay available post-event, ensuring that investors who cannot attend live can still access important information, enhancing transparency.
- Company Overview: Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company, dedicated to providing solutions for livestock producers, farmers, and veterinarians to maintain and enhance animal health, demonstrating its expertise and market position in the animal health sector.
See More
Phibro Animal Health Corporation Q3 2026 Earnings Highlights
- Significant Sales Growth: Phibro Animal Health Corporation reported net sales of $383 million in Q3, a 10% increase, indicating strong ongoing demand in the animal health sector, which is expected to further drive revenue growth in the future.
- Steady EBITDA Improvement: Adjusted EBITDA rose 11% to $60 million, reflecting the company's success in cost control and operational efficiency, thereby enhancing its financial stability and investment appeal.
- Launch of Sustainable Solutions Platform: The introduction of the new sustainability solutions platform, Verratain, aims to assist companies in achieving their environmental goals, potentially opening up multi-billion dollar market opportunities and enhancing competitive positioning.
- Enhanced Credit Flexibility: Phibro increased its revolving credit facility by $125 million through an oversubscribed process, further bolstering the company's financial flexibility and providing stronger support for future investments and expansions.
See More
Phibro Animal Health to Attend Healthcare Conference
- Conference Participation: Phibro Animal Health Corporation will participate in the Bank of America Securities Healthcare Conference on May 13, 2026, where executives will present the company's strategic and financial outlook to analysts and investors.
- Executive Lineup: The event will feature Executive Vice President and CEO Designate Daniel Bendheim, COO Larry Miller, and CFO Glenn David, showcasing the leadership team and strategic direction of the company.
- Live and Replay Access: The live audio presentation will be available on Phibro's Investor Relations website, ensuring that investors can access real-time information, while a replay will also be archived for later viewing, enhancing transparency and communication with stakeholders.
- Company Overview: Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company, committed to providing solutions that help livestock producers, farmers, and veterinarians maintain and enhance animal health, underscoring its significant role in the industry.
See More
Phibro Animal Q3 Earnings Beat Expectations
- Strong Earnings Performance: Phibro Animal Health reported a Q3 Non-GAAP EPS of $0.76, beating expectations by $0.05, indicating a sustained improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q3 revenue of $383.5 million, a 5.4% year-over-year increase, surpassing expectations by $16.48 million, demonstrating effective execution of sales strategies and solidifying its market position.
- Updated Future Guidance: Phibro updated its fiscal year 2026 guidance, projecting net sales between $1.46 billion and $1.50 billion, with adjusted EBITDA expected to be between $247 million and $255 million, reflecting management's confidence in future growth and strategic planning.
- Stock Price Volatility: Despite strong earnings, Phibro Animal's shares fell by 12.5%, potentially indicating market concerns about the broader economic environment, prompting investors to monitor subsequent market reactions.
See More
Phibro Animal Health CEO Sells Shares Amid Transition
- Share Reduction Details: Jack Bendheim, CEO of Phibro Animal Health, indirectly sold 18,608 shares of common stock between May 5 and May 7, 2026, totaling approximately $1 million, which reduced his indirect holdings from 74,760 to 56,152 shares, indicating a potential decrease in confidence regarding the company's future.
- Trading Plan Context: This sale was executed under a Rule 10b5-1 trading plan established on December 11, 2025, reflecting Bendheim's strategic adjustment ahead of his transition from CEO to Executive Chairman, suggesting a cautious approach during the governance change.
- Ownership Analysis: Despite the sale, Bendheim retains 16,840 direct shares and 56,152 indirect shares, totaling 449,485 Class A common stock shares convertible into common stock, indicating he still maintains significant economic interest and influence within the company.
- Company Performance Overview: Phibro Animal Health reported a revenue of $1.5 billion and a net income of $95.23 million, with a dividend yield of 1.88% and a 50.21% increase in stock price over the past year, highlighting the company's strong performance and growth potential in the animal health product market.
See More
Phibro Animal Health CEO Sells Shares
- Share Reduction Details: Jack Bendheim, CEO of Phibro Animal Health, sold 18,608 shares of common stock between May 5 and May 7, 2026, representing about 20% of his total reported ownership, indicating a gradual reduction in his stake in the company.
- Transaction Value Analysis: The sale, calculated at a weighted average purchase price of $54.61 per share according to SEC Form 4, reflects a significant transaction value, although Bendheim retains a solid ownership stake, suggesting confidence in the company's future.
- Management Transition Context: Bendheim established the sale plan in December 2025, coinciding with his announcement to step down as CEO on July 1, 2026, transitioning to Executive Chairman, which provides a reasonable context for his gradual divestment, typical for founder-era executives.
- Future Outlook and Challenges: With Daniel Bendheim taking over, investor focus will shift to sustaining the integration of Phibro's recent acquisition of Zoetis' feed additive portfolio and maintaining margin expansion, which will directly impact the company's long-term growth potential.
See More
Phibro Animal Health to Attend Stifel Conference
- Conference Participation: Phibro Animal Health Corporation will participate in the Stifel Jaws & Paws Conference on May 27, 2026, where executives will present the company's strategic and financial outlook, potentially boosting investor confidence.
- Executive Lineup: CEO designate Daniel Bendheim, COO Larry Miller, and CFO Glenn David will attend, showcasing the leadership team's expertise and commitment to future growth, which may attract more investor interest.
- Live and Replay Availability: The live audio presentation will be accessible on Phibro's Investor Relations website, with an archived replay available post-event, ensuring that investors who cannot attend live can still access important information, enhancing transparency.
- Company Overview: Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company, dedicated to providing solutions for livestock producers, farmers, and veterinarians to maintain and enhance animal health, demonstrating its expertise and market position in the animal health sector.
See More
Phibro Animal Health Corporation Q3 2026 Earnings Highlights
- Significant Sales Growth: Phibro Animal Health Corporation reported net sales of $383 million in Q3, a 10% increase, indicating strong ongoing demand in the animal health sector, which is expected to further drive revenue growth in the future.
- Steady EBITDA Improvement: Adjusted EBITDA rose 11% to $60 million, reflecting the company's success in cost control and operational efficiency, thereby enhancing its financial stability and investment appeal.
- Launch of Sustainable Solutions Platform: The introduction of the new sustainability solutions platform, Verratain, aims to assist companies in achieving their environmental goals, potentially opening up multi-billion dollar market opportunities and enhancing competitive positioning.
- Enhanced Credit Flexibility: Phibro increased its revolving credit facility by $125 million through an oversubscribed process, further bolstering the company's financial flexibility and providing stronger support for future investments and expansions.
See More
Phibro Animal Health to Attend Healthcare Conference
- Conference Participation: Phibro Animal Health Corporation will participate in the Bank of America Securities Healthcare Conference on May 13, 2026, where executives will present the company's strategic and financial outlook to analysts and investors.
- Executive Lineup: The event will feature Executive Vice President and CEO Designate Daniel Bendheim, COO Larry Miller, and CFO Glenn David, showcasing the leadership team and strategic direction of the company.
- Live and Replay Access: The live audio presentation will be available on Phibro's Investor Relations website, ensuring that investors can access real-time information, while a replay will also be archived for later viewing, enhancing transparency and communication with stakeholders.
- Company Overview: Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company, committed to providing solutions that help livestock producers, farmers, and veterinarians maintain and enhance animal health, underscoring its significant role in the industry.
See More
Phibro Animal Q3 Earnings Beat Expectations
- Strong Earnings Performance: Phibro Animal Health reported a Q3 Non-GAAP EPS of $0.76, beating expectations by $0.05, indicating a sustained improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q3 revenue of $383.5 million, a 5.4% year-over-year increase, surpassing expectations by $16.48 million, demonstrating effective execution of sales strategies and solidifying its market position.
- Updated Future Guidance: Phibro updated its fiscal year 2026 guidance, projecting net sales between $1.46 billion and $1.50 billion, with adjusted EBITDA expected to be between $247 million and $255 million, reflecting management's confidence in future growth and strategic planning.
- Stock Price Volatility: Despite strong earnings, Phibro Animal's shares fell by 12.5%, potentially indicating market concerns about the broader economic environment, prompting investors to monitor subsequent market reactions.
See More
